Tongee debuts at ANMA & IDDW 2025 | China's first-in-class intestinal interventional weight loss device, the Gastric Bypass Stent System, breaks new ground overseas, ushering in a new paradigm for weight loss treatment in Southeast Asia

From September 4th to 6th, 2025, the 8th Biennial Congress of the Asian Neurogastroenterology and Motility Association (ANMA) was co-hosted with the Indonesian Digestive Disease Week (IDDW) in Jakarta. Tongee, a key participant in the conference, launched its star medical product, the "Gastric Bypass Stent System," and not only received an invitation to deliver a keynote speech to share China's innovative achievements, but also played a key role in promoting the successful implementation of the first clinical operation in Southeast Asia. Following the official breakthrough of China's innovative medical devices in overseas markets, Tongee injects the "Chinese solution" into global obesity diagnosis and treatment with its strong technological capabilities.

International academic recognition

Chinese innovations garner high attention from global experts

ANMA & IDDW 2025, co-hosted by the Indonesian Society of Gastroenterology (ISG) and ANMA, serves as a core platform for testing technological innovations in the global digestive and weight loss fields. At the conference, Ms. Emily from the Medical Department of Tongee presented a keynote speech on the "Short-Term Results of the TONGEE Stent in Obesity Management", systematically presenting the breakthroughs in minimally invasiveness, reversibility, and metabolic benefits of this technology. By constructing a "metabolic regulation channel" in the duodenum through a 60-centimeter stent, this system achieves the dual weight control approach of "physical intervention + hormonal regulation", avoiding the invasive and irreversible limitations of traditional surgery while addressing the individual variability and long-term medication requirements of drug treatments.

The presentation sparked enthusiastic responses from international experts, with several participating scholars engaging in in-depth discussions on the technical principles, safety data, and clinical application scenarios. Dr. Handy Wing pointed out, "The incidence of obesity and metabolic diseases continues to rise in Southeast Asia, but minimally invasive weight loss technologies are relatively scarce. Tongee’s Gastric Bypass Stent System, with its precise design and robust clinical data, is expected to become a major breakthrough in the treatment of obesity in this region." This recognition is not only an affirmation of a single technology, but also an international endorsement of China's medical innovation capabilities.

Ten years of research and development

Driving technological breakthroughs based on clinical needs

The breakthrough of the Gastric Bypass Stent System in overseas markets stems from Tongee decade-long dedication to solving clinical pain points. Unlike traditional weight loss technologies, which focus solely on weight loss, this system was developed from the outset with three core requirements: safety, efficiency, and universal applicability. The Gastric Bypass Stent System takes into account both operational convenience and patient tolerance. Designed mechanism of action around "synergistic improvement of metabolism", it aims to simultaneously improve insulin resistance and liver function while reducing weight, which is perfectly suited to the treatment needs of high-incidence complications such as obesity combined with diabetes and fatty liver.

During the conference, Mr. Zuo Yuxing, Founder and CEO of Tongee, engaged in in-depth discussions with global experts, showcasing the innovative thinking of Chinese companies from technology research and development logic to clinical implementation path. "Our research and development always starts with 'solving real clinical problems'." Mr. Zuo emphasized, "We have collaborated with over 300 hospitals in China and accumulated over 1,500 clinical data. It is this commitment to evidence-based research that gives China's original technology the confidence to go global." Numerous representatives from international medical institutions expressed their interest in collaboration, building a bridge for the subsequent popularization of this technology in Southeast Asia.

Prof. Yelong Yeh Lee showed great attention and strong interest in the Gastric Bypass Stent System. He not only discussed the technical principles, operation procedures and clinical application details of the system on the spot, but also clearly expressed his willingness to visit China for study. He hopes to master the core points of this technology through systematic and professional training, and personally perform the first Gastric Bypass Stent System implantation in Malaysia, promoting the application of this innovative technology in Malaysia.

Clinical implementation milestones

The first overseas clinical implantation was successfully performed

Behind the international academic recognition lies the rapid translation of technology into clinical practice. Dr. Handy Wing has long focused on safer and more effective minimally invasive weight loss therapies in his clinical practice. After gaining a thorough understanding of the Tongee’s Gastric Bypass Stent System, Dr. Handy Wing expressed high recognition of its design concept and clinical effectiveness. He went to China to study and became the first international expert to receive the training certificate for the Gastric Bypass Stent Systems.

During the meeting, Dr. Handy Wing and the Tongee’s Medical team further discussed the key operational points and technical details of the Gastric Bypass Stent System. On September 4, 2025, Dr. Handy Wing successfully performed Southeast Asia's first Gastric Bypass Stent System implantation on an Indonesian patient. The successful completion of this surgery not only validated the technology's adaptability across diverse populations and medical settings, but also marked a new phase in Tongee's overseas expansion, moving from "academic exchange" to "clinical practice". Dr. Handy Wing said in his postoperative sharing, "This technology offers a new option for obese patients in Indonesia and Southeast Asia, and provides a key tool for upgrading the weight loss diagnosis and treatment system in our region."

At this conference, Tongee not only showcased its high-quality clinical evidence and technological innovation capabilities, but also received concrete cooperation intentions from multiple international medical institutions, providing strong support for its overseas market expansion. Looking to the future, Tongee will continue to deepen its strategic layout in Southeast Asian market, collaborating with local medical institutions and experts to jointly promote the implementation and popularization of innovative medical solutions. We hope that the Gastric Bypass Stent System will provide a safer, more effective, and reversible treatment option for more patients suffering from obesity and metabolic diseases, becoming a key force in driving innovation in interventional weight loss treatment in Southeast Asia and globally.